EN
  • FR
Contact
  • News
  • Media
  • Health professionals
  • CAREERS
  • Investors
LFB corp
  • The group
    • The LFB group
    • LFB Key dates
    • LFB Key dates
    • LFB worldwide
    • A special place in France
    • Governance
      • LFB SA Board of Directors
      • Group Executive Committee
      • LFB BIOMEDICAMENTS
      • LFB BIOTECHNOLOGIES
      • Composition and tasks of the Committees
  • Products and activities
    • Medicinal products
    • Biosafety
  • Innovation
    • Products under development
    • Technology platforms
    • Improving biosafety
  • Responsibilities
    • Rare diseases
    • Relations with patients’ associations
    • A responsible company
    • Transparency of interests for France
  • The LFB group

    LFB is a pharmaceutical group specialising in plasma derived or recombinant therapeutic proteins for the treatment of serious and often rare diseases.

  • LFB Key dates

    Since the creation of LFB in January 1994, discover the dates that gone down the Group's history.

  • LFB Key dates

    Since the creation of LFB in January 1994, discover the dates that gone down the Group's history.

  • LFB worldwide

    Worldwide, LFB has decided on a targeted strategy

  • A special place in France

    LFB has a special place in France, as a player in the healthcare industry with a public health mission

  • Governance

    A public company active in a competitive market

  • Medicinal products

    15 hospital-prescribed medicinal products

  • Biosafety

    Patient safety, a top priority for LFB

  • Products under development

    There are several medicinal products at an advanced stage of development, for registration in Europe and the USA

  • Technology platforms

    Two proprietary platforms for therapeutic and technological innovation

  • Improving biosafety

    Innovations to constantly improve the biosafety of medicinal products

  • Rare diseases

    LFB has a continuing commitment to social issues, offering several therapeutic solutions, both currently on sale and under development, for rare diseases

  • Relations with patients’ associations

    LFB is a partner in several patients’ associations and supports projects focused on a better quality of life for patients and their families

  • A responsible company

    LFB’s ethical commitment is reflected in the way it exercises its environmental, social and economic responsibilities

  • Transparency of interests for France

    Transparency of interests for France

Medicinal products
marketed in
40 countries

burger

Home › News

News

Find the latest news and press releases of LFB Group and its companies


22 Feb 2021

LFB is committed to patients suffering from rare coagulation disorders at GTH Congress 2021.

03 Feb 2021
LFB is committed to Von Willebrand disease at EAHAD 2021
25 Jan 2021
LFB 2021 corporate Brochure
25 Jan 2021
Découvrez la nouvelle Brochure du LFB
Take a look at the new LFB corporate brochure!
14 Jan 2021
WORKSHOP AT THE INTERNATIONAL VIRTUAL CONGRESS OF EURO-KiDs ON 14 JANUARY 2021
05 Jan 2021
Best wishes 2021
17 Dec 2020
CAHPP green index: LFB obtains A++ label
09 Dec 2020
82 SNFMI Congress 2020
LFB symposium AT THE SNFMI VIRTUAL congress ON December 9TH
08 Dec 2020
LFB opens the doors of the future Arras Factory
Read more

Follow us on

  • The group
    • The LFB group
    • LFB Key dates
    • LFB worldwide
    • A special place in France
      • A player in the healthcare industry
      • A public health mission in france
    • Governance
      • Group Executive Committee
      • LFB BIOMEDICAMENTS
      • LFB BIOTECHNOLOGIES
      • Composition and tasks of the Committees
  • Products and activities
    • Medicinal products
      • Immunology
      • Haemostasis
      • Intensive care
    • Biosafety
  • Innovation
    • Products under development
    • Technology platforms
      • EMABling®
      • rPRO™ technology
    • Improving biosafety
  • Responsibilities
    • Rare diseases
    • Relations with patients’ associations
    • A responsible company
      • Environmental responsibility
      • Social responsibility
      • Economic responsibility
    • Transparency of interests for France
  • Site map
  • Information notices
  • Adverse effect reporting
 
 
 

 

×